Osteoporosis Global Market 2016-2026

骨粗鬆症治療薬の世界市場2016-2026

◆タイトル:Osteoporosis Global Market 2016-2026
◆商品コード:VGAIN6041540
◆調査・発行会社:visiongain
◆発行日:2016年4月
◆ページ数:207
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥287,856見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥431,856見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥719,856見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"骨粗鬆症治療薬の世界市場2016-2026"について調査・分析し、レポートサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others – our new study reveals trends, R&D progress, and predicted revenuesWhere is the Osteoporosis Drugs market heading? Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 207 page report provides 140 charts. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Osteoporosis Drugs market.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
• Read full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
- Interview with Paul Mitchell, founder of Synthesis Medical, an independent healthcare consultancy
- Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist at Pursuit Physical Therapy

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets: Antiresorptive drugs, Anabolic drugs and Others. These submarkets are further broken down into bisphosphonates, selective oestrogen receptor modulators, RANKL antibodies and the parathyroid hormones.
Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those Osteoporosis Drugs?
How will individual osteoporosis drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these 13 brands:
1. Fosamax
2. Boniva/Bonviva
3. Actonel/Atelvia
4. Reclast/Aclasta
5. Recalbon/Bonoteo
6. Evista
7. Duavee
8. Prolia
9. Forteo
10. Odanacatib
11. Romosozumab
12. Protelos
13. Abaloparatide

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 12 leading national markets from 2016-2026:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).
• South Korea

Leading companies and the potential for market growth
You can also see which companies hold the most potential:
- Eli Lilly
- Amgen
- UCB
- GSK
- MSD
- Allergan
- Sanofi
- Pfizer
- Novartis
- Radius Health

【レポートの目次】

1. Report Overview
1.1 Overview of the Osteoporosis Industry and Market 2016-2026
1.2 Why You should Read this Report
1.3 How this Study Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Investigation for?
1.6 Method of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Reports
1.9 About visiongain

2. Introduction to Osteoporosis
2.1 Osteoporosis Prevalence and Incidence in 2015
2.2 Osteoporosis: The Silent Killer
2.3 Osteoblasts are Critical in Bone Healing
2.4 Classifying Osteoporosis by Types
2.5 Classifying Osteoporosis by Treatments
2.5.1 Antiresorptive Medication
2.5.2 Anabolic Medication
2.6 Osteoporosis Risk Factors

3. Global Forecast for the Osteoporosis Market 2016-2026
3.1 The Global Osteoporosis Drug Market in 2015
3.2 The Global Osteoporosis Drug Market Forecast, 2016-2026
3.3 The Global Osteoporosis Market by Main Therapeutic Class, 2016-2026
3.3.1 The Antiresorptive Drug Submarket
3.3.1.1 Antiresorptive Drug Submarket Forecast 2016-2026
3.3.2 The Anabolic Drug Submarket
3.3.2.1 Anabolic Drug Submarket Forecast 2016-2026
3.3.3 The Others Submarket
3.3.3.1 The Others Submarket Forecast 2016-2026
3.4 Drivers and Restraints for the Global Osteoporosis Market 2016-2026

4. Individual Osteoporosis Drug Revenue Forecasts 2016-2026
4.1 The Bisphosphonates Submarket
4.1.1 The Bisphosphonates Revenue Forecast, 2016-2026
4.1.2 Merck (MSD)’s Fosamax (Alendronate)
4.1.2.1 Generic Competition for Fosamax in 2016
4.1.2.2 Fosamax Market Forecast 2016-2026
4.1.3 Roche’s Bonviva/Boniva (Ibandronate)
4.1.3.1 Boniva/Bonviva Market Forecast 2016-2026
4.1.4 Sanofi’s Actonel/Atelvia (Risedronate)
4.1.4.1 Actonel/Atelvia Market Forecast 2016-2026
4.1.5 Novartis’ Reclast/Aclasta (Zoledronate)
4.1.5.1 Reclast/Aclasta (Zoledronate) in the Leading National Markets, 2016
4.1.5.2 Generic Competition for Reclast/Aclasta (Zoledronate), 2016
4.1.5.3 Reclast/Aclasta (Zoledronate) Market Forecast 2016-2026
4.1.6 Ono Pharmaceutical’s/Astellas’ Recalbon/Bonoteo (Minodronate)
4.1.6.1 Recalbon/Bonoteo Market Forecast, 2016-2026
4.2 The SERMs Submarket
4.2.1 The SERMs Revenue Forecast, 2016-2026
4.2.2 Eli Lilly’s Evista (Raloxifene)
4.2.2.1 Generic Raloxifene Slashes Evista Profits
4.2.2.2 Evista Market Forecast 2016-2026
4.2.3 Pfizer’s Duavee
4.2.3.1 Duavee Market Forecast 2016-2026
4.3 The Global RANKL Antibody Market Forecast, 2016-2026
4.3.1 Amgen’s Prolia (Denosumab)
4.3.1.1 History of Prolia (Denosumab)
4.3.1.2 Prolia (Denosumab) Market Forecast 2016-2026
4.4 The Parathyroid Hormone Submarket
4.4.1 Parathyroid Hormone Submarket Forecast 2016-2026
4.4.2 Eli Lilly’s Forteo (Teriparatide)
4.4.3 Forteo Market Forecast 2016-2026
4.4.4 Preotact/Preos Withdrawn from the Market
4.5 The Others Submarket
4.5.1 The Others Submarket Forecast 2016-2026
4.5.2 Servier’s Protelos (Strontium Ranelate) 2016-2026
4.5.3 Protelos Market Forecast 2016-2026

5. Pipeline Drugs for the Osteoporosis Market 2016-2026
5.1 Merck (MSD)’s Odanacatib (MK 0822)
5.1.1 Odanacatib Market Forecast 2016-2026
5.2 Amgen’s Romosozumab (AMG 785)
5.2.1 Romosozumab Market Forecast 2016-2026
5.3 Blosozumab (LY2541546)
5.4 Radius Health’s Abaloparatide (BA-058)
5.4.1 Abaloparatide Market Forecast 2016-2026
5.5 ZP-PTH: Parathyroid
5.6 ZT-034: Will Need More Than Biomarkers for Approval

6. National Submarkets for the Osteoporosis Market 2016-2026
6.1 The Global Osteoporosis Market by Regional Breakdown, 2015, 2020 and 2026
6.2 The Global Osteoporosis Market Forecast by Regional Breakdown, 2015, 2020 and 2026
6.3 The US Osteoporosis Drug Market, 2015
6.3.1 The US Osteoporosis Market Forecast, 2016-2026
6.3.2 The Reimbursement System of the US
6.3.3 The US Must Improve Osteoporosis Preventation Measures
6.3.4 Drivers and Restraints for the US Osteoporosis Market, 2016-2026
6.4 The EU5 Osteoporosis Osteoporosis Market Forecasts, 2016-2026
6.4.1 The German Osteoporosis Market Forecast, 2016-2026
6.4.2 The French Osteoporosis Market Forecast, 2016-2026
6.4.3 The UK Osteoporosis Drug Market Forecast, 2016-2026
6.4.4 The Italian Osteoporosis Market Forecast, 2016-2026
6.4.5 The Spanish Osteoporosis Market Forecast, 2016-2026
6.5 The Japanese Osteoporosis Drug Market, 2015
6.5.1 The Japanese Osteoporosis Market Forecast, 2016-2026
6.5.2 Recent Trends in the Japanese Osteoporosis Market
6.6 The BRIC Countries Osteoporosis Market, 2015
6.6.1 The BRIC Countries Osteoporosis Market Forecast, 2016-2026
6.6.2 The Chinese Osteoporosis Market Forecast, 2016-2026
6.6.2.1 Drivers of Growth in the Chinese Market
6.6.3 The Indian Osteoporosis Market Forecast, 2016-2026
6.6.4 The Russian Osteoporosis Market Forecast, 2016-2026
6.6.5 The Brazilian Osteoporosis Market Forecast, 2016-2026
6.7 The South Korean Osteoporosis Market, 2016-2026
6.8 The Osteoporosis Market for the Rest of the World, 2016-2026
6.9 Additional Considerations for the National Osteoporosis Markets

7. Market Leaders for the Osteoporosis Market 2016-2026
7.1 Market Leaders in 2015
7.2 Eli Lilly
7.2.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2016-2026
7.3 Amgen
7.3.1 Amgen: Reacquires All Rights for Prolia from GSK
7.3.2 Amgen Osteoporosis Drug Sales Forecast, 2016-2026
7.4 UCB
7.4.1 UCB Osteoporosis Drug Sales Forecast, 2016-2026
7.5 GSK
7.6 Merck and Co. (MSD)
7.6.1 Merck (MSD) Osteoporosis Drug Sales Forecast, 2016-2026
7.7 Allergan
7.8 Sanofi
7.9 Pfizer
7.10 Novartis
7.11 Radius Health

8. Qualitative Analysis of the Osteoporosis Market
8.1 SWOT (Strengths, Weaknesses, Opportunities and Threats) Analysis of the Osteoporosis Market, 2016-2026
8.2 STEP (Social, Technological, Economic and Political) Analysis of the Osteoporosis Market, 2016-2026

9. Research Interviews
9.1 Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
9.1.1 On the Problem of Osteoporosis in Today’s Society
9.1.2 On the Work of the National Osteoporosis Foundation
9.1.3 On Drug Treatments and the Prevention of Osteoporosis
9.2 Interview with Paul Mitchell, Founder of Synthesis Medical Limited
9.2.1 On the Work of Synthesis Medical
9.2.2 On the Burden of Osteoporosis to Society
9.2.3 On Education and Policy for Osteoporosis
9.2.4 On Primary and Secondary Fractures
9.2.5 On Drug Treatments and Innovation for Osteoporosis
9.3 Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist, Pursuit Physical Therapy
9.3.1 On the Therapy used at Pursuit Physical Therapy
9.3.2 On Primary and Secondary Fractures
9.3.3 On Education and Innovation for Osteoporosis

10. Conclusions
10.1 The Global Osteoporosis Market and Submarkets in 2015
10.2 The Global Osteoporosis Market and Submarkets until 2026
10.3 The National Markets for Osteoporosis in 2015
10.4 The National Markets for Osteoporosis until 2026
10.5 Leading Companies in the Osteoporosis Market
10.6 Drivers for the Osteoporosis Market
10.7 Challenges to Overcome for the Future Osteoporosis Drug Market

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 1.1 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 2.1 Mechanisms Involved in Bone Grafting
Table 3.1 Treatments for Osteoporosis, by Therapeutic Classes, Drug Category and Branded Drugs, 2016
Table 3.2 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
Table 3.3 The Global Osteoporosis Drug Market: Revenue ($m) and Market Shares (%) by Therapeutic Classes, 2015, 2020 and 2026
Table 3.4 The Global Antiresorptive Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
Table 3.5 The Global Anabolic Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
Table 3.6 The Others Submarket Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
Table 4.1 The Bisphosphonates Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.2 Fosamax Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.3 Boniva/Bonviva Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.4 Actonel/Atelvia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.5 Reclast/Aclasta Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.6 Recalbon/Bonoteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.7 The SERMs Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.8 Evista Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.9 Duavee Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.10 Prolia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.11 The PTH Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.12 Forteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.13 The Others Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 4.14 Protelos Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 5.1 Odanacatib Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 5.2 Romosozumab Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 5.3 Abaloparatide Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026
Table 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015, 2020 and 2026
Table 6.3 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.4 The US Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.5 The EU5 Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.6 The Median Ages in EU5 Nations from 1960 to 2060, by Country
Table 6.7 Germany Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.8 France Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.9 UK Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.10 Italy Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.11 Spain Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.12 Japan Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.13 The BRIC Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.14 China Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.15 India Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.16 Russia Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.17 Brazil Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.18 South Korea Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 6.19 RoW Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
Table 7.1 The Eli Lilly Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 7.2 The Amgen Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 7.3 The UCB Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 7.4 The Merck (MSD) Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 7.5 The Sanofi Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 7.6 The Pfizer Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 7.7 The Novartis Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 7.8 The Radius Health Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
Table 8.1 Strengths and Weaknesses of the Osteoporosis Market, 2016-2026
Table 8.2 Opportunities and Threats to the Osteoporosis Market, 2016-2026
Table 8.3 Social and Technological Factors of the Osteoporosis Market, 2016-2026
Table 8.4 Economic and Political Factors of the Osteoporosis Market, 2016-2026

List of Figures
Figure 1.1 Global Osteoporosis Drug Market Segmentation
Figure 3.1 The Global Osteoporosis Drug Market Revenue ($m) Forecast, 2016-2026
Figure 3.2 The Global Osteoporosis Drug Market AGR (%) Forecast, 2016-2026
Figure 3.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015
Figure 3.4 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2020
Figure 3.5 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026
Figure 3.6 Drivers and Restraints for the Osteoporosis Market, 2016-2026
Figure 4.1 The Bisphosphonates Revenue Forecast ($m), 2016-2026
Figure 4.2 The Bisphosphosphonates Drug Market AGR (%) Forecast, 2016-2026
Figure 4.3 Fosamax Revenue Forecast ($m), 2016-2026
Figure 4.4 Fosamax AGR (%) Forecast, 2016-2026
Figure 4.5 Boniva/Bonviva Revenue Forecast ($m), 2016-2026
Figure 4.6 Boniva/Bonviva AGR (%) Forecast, 2016-2026
Figure 4.7 Actonel/Ateliva Revenue Forecast ($m), 2016-2026
Figure 4.8 Actonel/Ateliva AGR (%) Forecast, 2016-2026
Figure 4.9 Reclast/Aclasta Revenue Forecast ($m), 2016-2026
Figure 4.10 Reclast/Aclasta AGR (%) Forecast, 2016-2026
Figure 4.11 Recalbon/Bonoteo Revenue Forecast ($m), 2016-2026
Figure 4.12 Recalbon/Bonoteo AGR (%) Forecast, 2016-2026
Figure 4.13 The SERMs Revenue Forecast ($m), 2016-2026
Figure 4.14 The SERMs AGR (%) Forecast, 2016-2026
Figure 4.15 Evista Revenue Forecast ($m), 2016-2026
Figure 4.16 Evista AGR (%) Forecast, 2016-2026
Figure 4.17 Duavee Revenue Forecast ($m), 2016-2026
Figure 4.18 Duavee AGR (%) Forecast, 2016-2026
Figure 4.19 Prolia Revenue Forecast ($m), 2016-2026
Figure 4.20 Prolia AGR (%) Forecast, 2016-2026
Figure 4.21 PTH Revenue Forecast ($m), 2016-2026
Figure 4.22 PTH AGR (%) Forecast, 2016-2026
Figure 4.23 Forteo Revenue Forecast ($m), 2016-2026
Figure 4.24 Forteo AGR (%) Forecast, 2016-2026
Figure 4.25 The Others Submarket Revenue Forecast ($m), 2016-2026
Figure 4.26 The Others Submarket AGR (%) Forecast, 2016-2026
Figure 4.27 Protelos Revenue Forecast ($m), 2016-2026
Figure 4.28 Protelos Submarket AGR (%) Forecast, 2016-2026
Figure 5.1 Odanacatib Revenue Forecast ($m), 2016-2026
Figure 5.2 Odanacatib Submarket AGR (%) Forecast, 2017-2026
Figure 5.3 Romosozumab Revenue Forecast ($m), 2016-2026
Figure 5.4 Romosozumab Submarket AGR (%) Forecast, 2017-2026
Figure 5.5 Abaloparatide Revenue Forecast ($m), 2016-2026
Figure 5.6 Abaloparatide Submarket AGR (%) Forecast, 2016-2026
Figure 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026
Figure 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015
Figure 6.3 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2020
Figure 6.4 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2026
Figure 6.5 The US Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.6 The US Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.7 Drivers and Restraints for the US Osteoporosis Market, 2016-2026
Figure 6.8 The EU5 Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.9 The EU5 Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.10 Germany Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.11 Germany Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.12 France Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.13 France Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.14 UK Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.15 UK Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.16 Italy Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.17 Italy Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.18 Spain Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.19 Spain Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.20 Japan Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.21 Japan Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.22 The BRIC Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.23 The BRIC Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.24 China Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.25 China Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.26 India Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.27 India Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.28 Russia Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.29 Russia Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.30 Brazil Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.31 Brazil Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.32 South Korea Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.33 South Korea Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 6.34 RoW Osteoporosis Market Revenue ($m) Forecast, 2016-2026
Figure 6.35 RoW Osteoporosis Market AGR (%) Forecast, 2016-2026
Figure 10.1 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015
Figure 10.2 The Global Osteoporosis Market by Individual Drug Market Share (%), 2015
Figure 10.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026
Figure 10.4 The Global Osteoporosis Drug Market Therapeutic Class Revenue ($m), 2015, 2020 and 2026
Figure 10.5 The Global Osteoporosis Market by Individual Drug Market Share (%), 2026
Figure 10.6 The Global Osteoporosis Market by National Market Share (%), 2015
Figure 10.7 The Global Osteoporosis Market by National Market Share (%), 2026
Figure 10.8 The Global Osteoporosis Market by Revenue ($m), 2015, 2020 and 2026

【レポートのキーワード】

骨粗鬆症、骨粗鬆症治療薬、骨吸収抑制薬

★調査レポート[骨粗鬆症治療薬の世界市場2016-2026] ( Osteoporosis Global Market 2016-2026 / VGAIN6041540) 販売に関する免責事項
[骨粗鬆症治療薬の世界市場2016-2026] ( Osteoporosis Global Market 2016-2026 / VGAIN6041540) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆